BEAM Beam Therapeutics Inc.

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

$92.45  -3.13 (-3.28%)
As of 03/02/2021 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
12/31/1997
57,965,991
1,065,408
$5,540,389,420
0.00%
SEC Edgar Online
10-Q
10-K
07373V105
US07373V1052
BK6L288

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-42.13
24.09
0.00
-63.47%
-529,075.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy